Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spontaneous retinal artery pulses as a prognostic determinant in central retinal vein occlusion
2020-005449-18Phase 4Active
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in central retinal vein occlusion (CRVO) (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Change in best corrected visual acuity (BCVA). Started Dec 2020; status: active.
02
Drugs
aflibercept
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2020-005449-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005449-18.